Tag: MyoVista

HeartSciences Named as a Top 10 Healthcare Artificial Intelligence Solutions Provider 2023 by Healthcare Tech Outlook Magazine

Southlake, Texas, May 17, 2023 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-based medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announces it has been recognized by Healthcare Tech Outlook Magazine as a 2023 […]

HeartSciences Granted European Patent for Proprietary Electrode and Cable Connections for Use with its AI-Based MyoVista® ECG

Patent builds on previously granted U.S. patent as well as strengthens and diversifies the IP portfolio and further protects future revenues Southlake, Texas, Oct. 25, 2022 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on saving lives by making […]

HeartSciences to Participate and Showcase the MyoVista at the Inauguration Ceremony of the Center for Innovation at Rutgers Robert Wood Johnson University Hospital

Southlake, Texas, Sept. 12, 2022 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc d.b.a HeartSciences (NASDAQ: HSCS), a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to significantly expand and improve an ECG’s clinical usefulness by detecting cardiac dysfunction, today announced that […]

HeartSciences Showcases MyoVista® Wavelet ECG at 2018 Scientific Sessions of the American Heart Association (AHA)

SOUTHLAKE, Texas–(BUSINESS WIRE)–HeartSciences, a medical device company developing next generation ECG devices using continuous wavelet transform (CWT) signal processing, is proud to announce its participation as an exhibitor at the upcoming 2018 Scientific Sessions of the American Heart Association (AHA). The AHA Congress will take place November 10-12, 2018 at […]

HeartSciences Showcases MyoVista® Wavelet ECG at 2018 European Society of Cardiology Congress (ESC)

SOUTHLAKE, Texas–(BUSINESS WIRE)–HeartSciences, a medical device company developing next generation ECG devices using continuous wavelet transform (CWT) signal processing and artificial intelligence, is proud to announce its participation as an exhibitor at the upcoming 2018 European Society of Cardiology Congress (ESC). The Congress will take place at Messe Munich International […]

HeartSciences Showcases MyoVista® Wavelet ECG at the 2018 International Congress on Electrocardiology (ICE)

SOUTHLAKE, Texas–(BUSINESS WIRE)–HeartSciences, an innovative medical device company, is proud to announce its participation as an exhibitor at the upcoming 2018 International Congress on Electrocardiology (ICE), which will be held in Makuhari Messe, Chiba City, Japan, June 28-30, 2018. ICE2018 will be the joint meeting of the 45th Congress of […]

HeartSciences Announces Publication of Clinical Trial Results in Journal of the American College of Cardiology (JACC)

SOUTHLAKE, Texas – ( BUSINESS WIRE ) – HeartSciences , a medical device company that is at the forefront of innovation in the field of electrocardiography thanks to the application of artificial intelligence and signal processing based on continuous waveforms (continuous wavelet transform, CWT), today announced the results of a clinical study conducted serially […]